Loading clinical trials...
Loading clinical trials...
To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Merrimack Pharmaceuticals
Collaborators
NCT07060989 · Advanced Solid Tumors
NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more
NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more
NCT05533697 · Advanced Solid Tumors
Lafayette, Indiana
Buffalo, New York
Cincinnati, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions